TABLE 1.
Serum HAI antibody titers and GMFRs in response to the A/H1N1, A/H3N2, and B virus strains in all subjects
| Strain and treatment | nb | Geometric meana HAI titer (95% CI)
|
GMFR (95% CI) | |
|---|---|---|---|---|
| Prevaccination | Postvaccination | |||
| A/H1N1 | ||||
| CAIV-T 107 | 40 | 3.86 (2.39, 6.24) | 6.96 (3.94, 12.30) | 1.8 (1.19, 2.74) |
| CAIV-T <105 | 40 | 4.84 (2.85, 8.23) | 4.84 (2.83, 8.27) | 1.00 (0.74, 1.35) |
| TIV | 42 | 5.56 (3.21, 9.63) | 13.34 (5.75, 30.95) | 2.40 (1.62, 3.54) |
| Placebo | 40 | 5.10 (3.01, 8.64) | 5.01 (2.99, 8.39) | 0.98 (0.68, 1.42) |
| A/H3N2 | ||||
| CAIV-T 107 | 40 | 4.07 (2.50, 6.63) | 28.34 (17.03, 47.16) | 6.96 (3.95, 12.27) |
| CAIV-T <105 | 40 | 3.93 (2.41, 6.42) | 4.68 (2.79, 7.83) | 1.19 (0.88, 1.61) |
| TIV | 42 | 4.00 (2.45, 6.52) | 6.90 (3.90, 12.19) | 1.72 (1.34, 2.21) |
| Placebo | 40 | 3.93 (2.41, 6.40) | 4.68 (2.76, 7.91) | 1.19 (0.91, 1.56) |
| B | ||||
| CAIV-T 107 | 40 | 5.76 (3.58, 9.27) | 16.00 (10.51, 24.35) | 2.78 (1.46, 5.29) |
| CAIV-T <105 | 39 | 6.28 (4.17, 9.45)c | 7.72 (4.79, 12.45) | 1.28 (0.88, 1.88) |
| TIV | 42 | 5.38 (3.60, 8.05) | 10.42 (5.49, 19.76) | 1.94 (1.25, 3.00) |
| Placebo | 39 | 5.51 (3.66, 8.29) | 7.45 (4.86, 11.43) | 1.35 (0.82, 2.22) |
a
Geometric mean, antilog of the mean of the log-transformed titer or fold rise.
b
n, number of subjects in the calculation.
c
A total of 40 subjects were included for this calculation.